Decoy Therapeutics Inc

This management proposal seeks shareholder approval of the Decoy Therapeutics Inc. 2026 Equity Incentive Plan, which would authorize an initial 1,100,000-share reserve (subject to specified annual automatic increases and adjustment mechanics) for grants of options, SARs, restricted stock, RSUs, performance awards and other equity/cash awards to employees, directors and consultants. Management states the Plan is intended to replace an expired 2015 plan and to provide a competitive equity tool to attract and retain personnel and align their interests with stockholders. The Plan delegates administration to the Board or a committee (currently the Compensation Committee) with broad discretion over grant terms, recipients, and vesting; it also permits customary adjustments for corporate events and contains clawback, transferability and Section 409A/422 compliance provisions. Key governance points include ability to reprice or modify awards with participant consent, full Board authority to amend the plan (subject to stockholder approval where required), and an annual automatic share-reserve increase formula that could dilute existing holders over time absent Board restraint. From a compensation governance perspective, the plan grants managers substantial discretion (including accelerated vesting on corporate events) which can be efficient for retention but raises oversight considerations if there are no pre-set caps for executive-level awards. The company discloses no awards are guaranteed now and that future grants are discretionary; it also states approximately ten employees and six non-employee directors would be eligible, indicating a relatively small participant population initially. Financially, the potential impact depends on future grant sizes and exercise behavior, but the plan includes customary anti-dilution and capitalization adjustment protections. The Board recommends a FOR vote emphasizing the need to recruit and retain talent post-merger and to align management incentives with stockholder value creation.

This management proposal asks shareholders to authorize a flexible reverse stock split (ratios between 1-for-4 and 1-for-15) with the Board empowered to select whether and when to effect the split (but not later than February 24, 2027) and to choose the specific ratio within the approved range. The Board frames the split as a tool to raise the per-share trading price to meet Nasdaq’s initial listing requirements following the Decoy Transaction and restore compliance with Nasdaq’s minimum bid price rules; the filing discloses the company recently received a Nasdaq notice of non-compliance for minimum bid price and appealed that determination, and that a reverse split is believed necessary to meet Nasdaq’s $4.00 per share initial-listing target. The flexible-range approach provides the Board discretion to respond to market conditions, which can be valuable given the company’s pending listing and conversion issues, but it also concentrates significant authority in the Board (including the ability to abandon the split even after shareholder approval). The proposal explains the mechanics: uniform treatment of shareholders, elimination or cash-out of fractional shares, adjustment of outstanding options, warrants and preferred conversion ratios as applicable, and no change to par value or authorized share counts. Risks disclosed include the possibility the split will not increase market capitalization or sustain higher pricing, potential harm to liquidity from fewer outstanding shares, increased odd-lot holdings, and the potential for increased authorized-but-unissued shares to be used for dilutive financings or anti-takeover purposes. The Board states it will not select a split that would leave fewer than 1,000,000 publicly held shares and reserves the right to decide timing based on trading, Nasdaq progress, and market conditions. For investors, the key evaluation points are whether the anticipated Nasdaq benefits outweigh the usual risks of reverse splits, whether management’s delegated discretion is appropriately constrained, and how the split interacts with the company’s pending preferred-stock conversion and capital plan.

This management proposal requests authority to adjourn or postpone the Special Meeting, if a quorum is present but there are insufficient votes to approve the Equity Incentive Plan or the Reverse Stock Split, so that the company can continue to solicit additional proxies. It's a procedural but practical mechanism that provides the Board flexibility to extend outreach and voting deadlines to achieve required vote thresholds without having to reconvene a new meeting. The proposal is routine in form and grants proxies authority for successive adjournments, which expedites repeated solicitations if needed. From a governance perspective, the adjournment power can be used to facilitate shareholder engagement and avoid rushed decisions, but it can also be used to delay outcomes; the company discloses that abstentions count as against the proposal when a quorum is present and that broker discretionary votes are permitted. The Board recommends a FOR vote, framing the adjournment as necessary only to secure adequate voting to approve Proposals 1 and 2. Institutional investors typically view such adjournment requests as neutral but will watch for whether the Board uses the power in a manner that advances shareholder interests versus management entrenchment. Overall, the proposal is administrative in nature but important to the company’s ability to complete the actions it says are conditional on shareholder approval.